Medicus Pharma (MDCX) News Today $4.27 -0.14 (-3.17%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Medicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $14.00 target price on shares of Medicus Pharma in a report on Monday.April 30, 2025 | marketbeat.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalApril 30, 2025 | americanbankingnews.comMedicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comMedicus Pharma (NASDAQ:MDCX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $14.00 price objective on shares of Medicus Pharma in a report on Monday.April 23, 2025 | marketbeat.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comD. Boral Capital Initiates Coverage of Medicus Pharma (MDCX) with Buy RecommendationApril 14, 2025 | msn.comResearch Analysts Set Expectations for Medicus Pharma Q1 EarningsMedicus Pharma Ltd. (NASDAQ:MDCX - Free Report) - Analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for Medicus Pharma in a research report issued to clients and investors on Tuesday, April 8th. Brookline Capital Management analyst K. Raja forecasts that tApril 12, 2025 | marketbeat.comMedicus Pharma Ltd. (MDCX)March 25, 2025 | finance.yahoo.comMedicus Pharma announces annual meeting dateMarch 22, 2025 | investing.comMedicus Pharma Secures $4.2 Million for Innovative Skin Treatment TrialsMarch 10, 2025 | tipranks.comMedicus Pharma CEO discusses latest skin cancer trial results - ICYMIMarch 8, 2025 | proactiveinvestors.comMedicus Pharma unveils pricing of financing to advance skin cancer treatmentMarch 7, 2025 | proactiveinvestors.comMedicus Pharma announces positively trending interim analysis for SKNJCT-003March 6, 2025 | markets.businessinsider.comMedicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim resultsMarch 6, 2025 | proactiveinvestors.comMedicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)March 6, 2025 | globenewswire.comMedicus Pharma Submits Phase 2 Clinical Trial Design For Non-Invasive BCC Treatment To UAEMarch 1, 2025 | nasdaq.comMedicus Pharma submits Phase 2 carcinoma clinical design in UAEFebruary 27, 2025 | markets.businessinsider.comMedicus Pharma submits Phase 2 skin cancer trial design to UAE Department of HealthFebruary 27, 2025 | proactiveinvestors.comMedicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)February 27, 2025 | globenewswire.comMedicus Pharma's Phase 2 skin cancer trial hits key milestone - ICYMIFebruary 22, 2025 | proactiveinvestors.comPromising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.February 15, 2025 | tipranks.comMedicus Pharma Ltd: Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)February 15, 2025 | finanznachrichten.deMedicus Pharma announces phase 2 study SKNJCT-003 underwayFebruary 14, 2025 | markets.businessinsider.comMedicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-endFebruary 14, 2025 | proactiveinvestors.comMedicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)February 14, 2025 | globenewswire.comMedicus Pharma Ltd MDCXFebruary 12, 2025 | morningstar.comMedicus Pharma enters SEPA, intends to voluntarily delist from TSXFebruary 12, 2025 | markets.businessinsider.comMedicus Pharma secures $15 million funding optionFebruary 12, 2025 | msn.comMedicus Pharma announces equity deal, shifts focus to NasdaqFebruary 11, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)February 11, 2025 | globenewswire.comMedicus Pharma Ltd. Announces Change of AuditorDecember 26, 2024 | tipranks.comMedicus Pharma CEO charts course for 2025 with clinical milestones for SkinJectDecember 23, 2024 | proactiveinvestors.comMedicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMIDecember 20, 2024 | proactiveinvestors.comMedicus Pharma's horse skin cancer treatment wins MUMS designation from FDADecember 12, 2024 | proactiveinvestors.comMedicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) PatchDecember 12, 2024 | globenewswire.comMedicus Pharma CEO on basal-cell carcinoma trial progress – ICYMIDecember 7, 2024 | proactiveinvestors.comMedicus Pharma CEO on basal-cell carcinoma trial progress – ICYMIDecember 7, 2024 | proactiveinvestors.comMedicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progressesDecember 2, 2024 | proactiveinvestors.comMedicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-PacificDecember 2, 2024 | proactiveinvestors.com Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Media Mentions By Week MDCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDCX News Sentiment▼0.200.72▲Average Medical News Sentiment MDCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDCX Articles This Week▼52▲MDCX Articles Average Week Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Humacyte News Amarin News Ocugen News Bright Minds Biosciences News enGene News SOPHiA GENETICS News CARGO Therapeutics News Fulcrum Therapeutics News Genfit News Annexon News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDCX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
